Original Research

Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database

Qiuyan Lin 1 | Xiaoquan Huang 2 | Canmei Zhong 1 | Tiancheng Luo 2 | Xiaoqing Zeng 2 | Shiyao Chen 2

1Department of Gastroenterology, Union Hospital, Fujian Medical University, Fuzhou, China
2Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China

Correspondence
Shiyao Chen, Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
Email: Chen.shiyao@zs-hospital.sh.cn

Funding information
This work was supported by the Foundation of Discipline Construction of Evidence-based Medicine Center, Zhongshan Hospital, China. And the study was partly supported by the 3-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System (No. 15GWZK0901) and Youth fund of shanghai Municipal Commission of Health and Family Planning (grant no. 20154Y0065). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract
Objectives: Hepatocellular carcinoma (HCC) associated with major vascular invasion is an advanced stage disease with an extremely poor prognosis and low survival rate. Our study evaluated the survival benefit of radiotherapy (RT) in HCC patients with major vascular invasion through Surveillance, Epidemiology, and End Results database.

Methods: We analyzed 3181 HCC patients with major vascular invasion cases diagnosed from 2004 to 2013. Patients (N = 308) who underwent RT and patients (N = 2873) who did not receive RT were compared. We successfully analyzed patients using propensity score matching (PSM). Kaplan-Meier and Cox-regression analyses were applied to assess prognosis.

Results: The median survival time in radiation-treated group was longer compared to the control group (7 months vs 3 months; \( P < 0.001 \)) in the overall sample and 3 months longer compared to the control group (7 months vs 4 months; \( P < 0.001 \)) in a PSM cohort. Cox-regression analyses showed that radiation-treated patients in propensity-matched sample had a significantly lower risk of mortality (HR: 0.625, 95% CI: 0.522-0.749, \( P < 0.001 \)) compared with untreated patients. The radiation-treated groups had better survival rate than untreated group. Subgroup analysis revealed that the survival time of patients in radiation-treated group was significantly longer than that in the untreated group (\( P < 0.001 \) and \( P = 0.026 \), respectively). The subgroup analysis also revealed that RT provides a survival benefit regardless of race, marital status, and tumor size after PSM.

Conclusions: Radiotherapy provides improves survival in HCC patients with major vascular invasion, especially for tumor(s) confined to one lobe and not on surface of liver.

Keywords
hepatocellular carcinoma, major vascular invasion, propensity score-match, radiotherapy, Surveillance, Epidemiology, and End Results

Qiuyan Lin and Xiaoquan Huang are contributed equally to the manuscript and share first authorship.
1 | INTRODUCTION

According to GLOBOCAN 2012 of the International Agency for Research on Cancer estimates, primary liver cancer is the fifth most frequently diagnosed cancers and second most common cause of cancer-related deaths worldwide among men. The most frequent liver cancer in about 70%-90% of patients is HCC. Patients with HCC are prone to vascular invasion and accompanied by dismal prognosis, which frequently arises in the portal vein, the hepatic/cava vein branches, or seldom the hepatic arteries. In particular, approximately 30%-40% cases of advanced HCC are accompanied by portal vein tumor thrombosis (PVTT). More pressingly, according to Barcelona Clinic for Liver Cancer (BCLC) Staging System, HCC associated with major vascular invasion is defined as an advanced stage, with an extremely poor prognosis and dismal survival rate. Regular surveillance can help in the early detection of the disease in patients who are at risk, but many patients are already in the intermediate or advanced stage when diagnosed.

Although surgical resection, transarterial chemoembolization (TACE), radiofrequency ablation and liver transplantation have significantly improved the survival rate of patients with HCC, it is prone to tumor recurrence, and the prognosis of advanced HCC still remained unsatisfactory. Sorafenib significantly improved the median survival and the time to radiologic progression by nearly 3 months longer for patients with advanced HCC in a multicenter, phase III, placebo-controlled trial. However, the application of sorafenib was limited because of grade 3/4 adverse events such as diarrhea, fatigue, and hand-foot skin reaction, and discontinuation or dose reduction of sorafenib are frequently performed. Although recent studies suggested that surgical resection of the liver improved the survival in patients with PVTT or hepatic vein invasion (HVTT), not all patients are eligible for this surgery.

Thus far, although more different treatment strategies have been utilized, the prognosis of patients accompanied by advanced HCC associated with major vascular invasion still remained poor. Therefore, more effective treatment to improve the prognosis of patients is urgently required. The primary endpoint of this study was overall survival (OS). Using chi-square test, patient characteristics were compared by univariate analysis, setting the caliper as 0.02. The PSM process has been applied to minimize selection bias and approximately balanced the baseline covariates under analytic settings between the groups.

2 | MATERIALS AND METHODS

2.1 | Study population

We obtained data from the SEER database of the National Cancer Institute (NCI) and performed a retrospective cohort study with cases diagnosed from 2004 to 2013. SEER is an open-access cancer database of the United States from 18 population-based cancer registries. SEER currently collects and publishes cancer incidence and survival data covering approximately 28% of the US population and is representative of demographic data. We acquired patients diagnosed with HCC from SEER database in accordance with International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), histology codes 8170 through 8175 for HCC, and site code C22.0 for liver, not included mixed HCC. We included patients with HCC extension to vascular invasion (code 630, 635, 660). According to Collaborative Stage Data Collection System Coding Instructions, Part II, Version 02.05, Effective January 1, 2014, major vascular invasion is considered as major branch(es) of portal or hepatic vein(s). Code 630 is major vascular invasion with single tumor (confined to one lobe) or multiple tumor(s) (confined to one lobe and not on the surface of the liver). Code 635 is major branch(es) of portal or hepatic vein(s) plus multiple nodules/tumors in more than one lobe of liver or on the surface of parenchyma. To identify control patients, we excluded patients who were unavailable for radiation, and had refused the recommended radiation, but unknown if administered. Follow-up time of the patients was from HCC diagnosis till death or end of the follow-up period.

2.2 | Propensity score matching (PSM)

The purpose of this article was to compare the benefits of RT for HCC patients with vascular invasion. This was an observational study and so the radiation assignment was not random. Some crucial covariates of the patients in the active treatment and control groups were heterogeneous and possibly affected the outcomes. Therefore, we further compared the survival rate between the radiation-treated and untreated cohorts by using the 1:1 nearest neighbor matching by univariate analysis, setting the caliper as 0.02. The PSM process has been applied to minimize selection bias and approximately balanced the baseline covariates under analytic settings between the groups.

2.3 | Statistical analysis

The primary endpoint of this study was overall survival (OS). Using chi-square test, patient characteristics were compared...
between radiation-treated and control patients. Covariates in the study included multiple level factors (such as age, gender, race, tumor size, vascular invasion, primary tumor lesion, node, metastasis, stage refer to Derived AJCC Stage Group (6th), differentiation grade, AFP, and degree of fibrosis). The SEER data recorded a small number of tumor lesions that are larger than 20 cm. We thought that these may be inconceivable, and so were included to know the participation statistics partially. The propensity score was used to reduce the selection bias. Kaplan-Meier analysis was used to estimate OS before and after PSM. We conducted a log-rank test to compare the survival differences for patients, lesions, and treatment-related characteristics. For multivariate analysis in the matched population, we constructed a Cox proportional hazards model to identify the predictors of survival. P values <0.05 were considered to be statistically significant. All statistical analyses were performed with IBM SPSS Statistics 22.0 (IBM, Armonk, NY, USA).

3 | RESULTS

3.1 | Baseline Characteristics

From 2004 to 2013, 53,842 patients with newly diagnosed HCC were identified in the SEER data set. Based on the eligibility criteria (described in the study population), a total of 5,166 patients diagnosed with advanced HCC associated with major vascular invasion were selected. Of these, 3,181 met the inclusion criteria of the study. The radiation-treated and untreated cohorts included 308 (9.7%) and 2,873 (90.3%) patients, respectively (Figure 1). Baseline characteristics of the patients, tumor, and treatment-related factors are summarized in Table 1.

3.2 | Survival before and after PSM

The 3-month, 6-month, 1-year, 3-year, and 5-year actuarial survival rates for the radiation treated and untreated groups were 78.1%, 55.0%, 31.3%, 12.1%, and 6.3% vs 49.6%, 30.4%, 16.1%, 4.3%, and 2.3%, respectively (Table 2). The Kaplan-Meier analyses indicated that the radiation-treated patients had a significantly better overall survival compared with control patients ($P < 0.001$, Figure 2A). Median survival for patients treated with radiation from the time of HCC diagnosis was 7 (IQR = 4-15) months, while the median survival of the control groups was 3 (IQR = 2-8) months.

After matching the radiation-treated to control patients with propensity scores, we balanced almost all the available covariates between the groups, while few covariates such as race, marital status, and tumor sizes showed differences. There were 308 radiation-treated patients and 308 untreated patients matching after excluding the unmatched populations (Table 1). The survival time between the radiation-treated and the untreated patients also showed significant differences after PSM to balance the covariates ($P < 0.001$, Figure 2B). The 3-month, 6-month, 1-year, 3-year, and 5-year actuarial survival for the radiation-treated group and untreated group after PSM were 78.1%, 55.0%, 31.3%, 12.1%, and 6.3% vs 52.5%, 31.0%, 17.0%, 4.4%, and 1.4%, respectively.
| Variables                  | Overall sample (n = 3181) | Propensity-matched sample (n = 616) |
|----------------------------|---------------------------|-------------------------------------|
|                            | Radiation (n = 308)       | Control (n = 2873)                  | Radiation (n = 308) | Control (n = 308) |
| Age (y)                    |                           |                                     |                      |                   |
| ≤65                        | 212 (68.8)                | 2020 (70.3)                         | 212 (68.8)          | 204 (66.2)        |
| >65                        | 96 (31.2)                 | 853 (29.7)                          | 96 (31.2)           | 104 (33.8)        |
| P value                    | 0.59                      |                                     |                      | 0.491             |
| Sex                        |                           |                                     |                      |                   |
| Male (%)                   | 251 (81.5)                | 2393 (83.3)                         | 251 (81.5)          | 250 (81.2)        |
| Female (%)                 | 57 (18.5)                 | 480 (16.7)                          | 57 (18.5)           | 58 (18.8)         |
| P value                    | 0.423                     |                                     |                      | 0.918             |
| Marital status             |                           |                                     |                      |                   |
| Married (%)                | 189 (61.4)                | 1489 (51.8)                         | 189 (61.4)          | 155 (50.3)        |
| Single and unmarried (%)   | 45 (14.6)                 | 659 (22.9)                          | 45 (14.6)           | 86 (27.9)         |
| Widowed, divorced, separated (%) | 60 (19.5)       | 596 (20.7)                          | 60 (19.5)           | 63 (20.5)         |
| Unknown (%)                | 14 (4.5)                  | 129 (4.5)                           | 14 (4.5)            | 4 (1.3)           |
| P value                    | 0.003                     |                                     |                      | <0.001            |
| Race                       |                           |                                     |                      |                   |
| White (%)                  | 224 (72.7)                | 1852 (64.5)                         | 224 (72.7)          | 180 (58.4)        |
| Black (%)                  | 43 (14.0)                 | 451 (15.7)                          | 43 (14.0)           | 46 (14.9)         |
| Other (%)                  | 41 (13.3)                 | 551 (19.2)                          | 41 (13.3)           | 82 (26.6)         |
| Unknown (%)                | 0 (0.0)                   | 19 (0.7)                            |                      |                   |
| Tumor size                 |                           |                                     |                      |                   |
| ≤1 cm (%)                  | 0 (0.0)                   | 14 (0.5)                            | 0 (0.0)             | 3 (1.0)           |
| 1-3 cm (%)                 | 26 (8.4)                  | 209 (7.3)                           | 26 (8.4)            | 18 (5.8)          |
| 3-5 cm (%)                 | 47 (15.3)                 | 368 (12.8)                          | 47 (15.3)           | 46 (14.9)         |
| >5 cm (%)                  | 185 (60.1)                | 1563 (54.4)                         | 185 (60.1)          | 168 (54.5)        |
| Unknown (%)                | 50 (16.2)                 | 719 (25.0)                          | 50 (16.2)           | 73 (23.7)         |
| P value                    | 0.008                     |                                     |                      | 0.048             |
| Vascular invasion          |                           |                                     |                      |                   |
| Code 630 (%)               | 185 (60.1)                | 1834 (63.8)                         | 185 (60.1)          | 193 (62.7)        |
| Code 635 (%)               | 87 (28.2)                 | 685 (23.8)                          | 87 (28.2)           | 73 (23.7)         |
| Code 660 (%)               | 36 (11.7)                 | 354 (12.3)                          | 36 (11.7)           | 42 (13.6)         |
| TNM/T                      |                           |                                     |                      |                   |
| T3 (%)                     | 272 (88.3)                | 2519 (87.7)                         | 272 (88.3)          | 266 (86.4)        |
| T4 (%)                     | 36 (11.7)                 | 354 (12.3)                          | 36 (11.7)           | 42 (13.6)         |
| P value                    | 0.747                     |                                     |                      | 0.467             |
| Lymph nodes                |                           |                                     |                      |                   |
| N0 (%)                     | 232 (75.3)                | 2020 (70.3)                         | 232 (75.3)          | 209 (67.9)        |
| N1 (%)                     | 51 (16.6)                 | 457 (15.9)                          | 51 (16.6)           | 66 (21.4)         |
| Nx (%)                     | 25 (8.1)                  | 396 (13.8)                          | 25 (8.1)            | 33 (10.7)         |
| P value                    | 0.02                      |                                     |                      | 0.121             |
| Distant metastasis         |                           |                                     |                      |                   |
| M0 (%)                     | 213 (69.2)                | 2038 (70.9)                         | 213 (69.2)          | 214 (69.5)        |
| M1 (%)                     | 85 (27.6)                 | 660 (23.0)                          | 85 (27.6)           | 86 (27.9)         |
| Mx (%)                     | 10 (3.2)                  | 175 (6.1)                           | 10 (3.2)            | 8 (2.6)           |
| P value                    | 0.038                     |                                     |                      | 0.891             |
| Derived AJCC Stage Group   |                           |                                     |                      |                   |
| (6th)                      |                           |                                     |                      |                   |
| III (%)                    | 213 (69.2)                | 2038 (70.9)                         | 213 (69.2)          | 214 (69.5)        |
| IV (%)                     | 85 (27.6)                 | 660 (23.0)                          | 85 (27.6)           | 86 (27.9)         |
| Unk stage (%)              | 10 (3.2)                  | 175 (6.1)                           | 10 (3.2)            | 8 (2.6)           |

**TABLE 1** Summary characteristics of the overall sample stratified by radiation treatment before and after propensity score matching.
Median survival of the radiation-treated patients was 7 (IQR = 4-15) months and that of the untreated patients was 4 (IQR = 2-9) months after PSM.

3.3 Prognostic factors

Table 3 listed the results of univariate Kaplan-Meier analysis in the matched population and 6-month survival rate. Significant differences in the survival rate were seen in covariates with radiation ($P < 0.001$), tumor size ($P = 0.022$), lymph nodes ($P < 0.001$), distant metastasis ($P < 0.001$), AJCC Stage (6th) ($P < 0.001$), and AFP level ($P < 0.003$). The patients with distant metastasis M1 and AJCC stage (6th) IV had worst survival and 6-months survival rate was only 22.1%.

Multivariate predictors of mortality in the propensity-matched samples are shown in Table 4. Radiation-treated patients in propensity-matched sample had a significantly lower risk of mortality (HR: 0.625, 95% CI: 0.522-0.749, $P < 0.001$) compared with untreated patients, respectively. Distant metastasis (M1) and AJCC Stage (6th) IV were independently associated with higher mortality rate ($P < 0.001$ and <0.001, respectively). Patients with elevated AFP levels were associated with higher mortality rate than patients with normal limits.

3.4 Predictors of survival among radiation-treated patients

Predictors of survival among radiation-treated patients were evaluated with multivariate analysis, and the results were shown in Table 5. The radiation-treated single and unmarried patients demonstrated better survival than the married patients (HR = 0.538, 95% CI: 0.347-0.834, $P = 0.006$). The radiation-treated patients of tumor size >5 cm had significantly worse mortality compared with radiation-treated patients of tumor size 1-3 cm (HR 1.836, 95% CI: 1.050-3.211, $P = 0.033$). Overall, the survival among radiation-treated patients was significantly associated with distant metastasis and AJCC Stage (Both HR: 3.197, 95% CI: 2.287-4.469, $P < 0.001$). Elevated AFP levels and Fibrosis score F1 were associated with higher mortality risk ($P < 0.001$ and <0.001, respectively).
significantly associated with increased risk of mortality ($P < 0.05$).

### 3.5 | Subgroup analysis after PSM

Subgroup analysis was performed on different types of vascular invasions, and the results showed that the survival time of patients with RT in Code 630 and Code 660 subgroup was significantly longer than that in the untreated group ($P < 0.001$ and $P = 0.026$, respectively). The survival rate of patients in the Code 635 group was not significantly affected by RT, but the median survival time was 6 months (95% CI: 4.36-7.64) in the radiation-treated group, which was longer than 4 months (95% CI: 2.5-5.5) in the untreated group ($P = 0.079$, Figure 3).

After PSM, marital status, race, and tumor size still demonstrated group differences, and so further subgroup analysis was performed. Overall survival in radiation-treated patients after PSM were significantly longer than untreated patients according to subgroup analysis of race white, black, and others ($P < 0.001$, $P = 0.002$ and $P = 0.008$, respectively, Figure 4).

In the marital status subgroup, the survival rate of married patients with RT was significantly higher than that in the untreated group ($P < 0.001$). The survival rate of single and unmarried group patients with RT was significantly higher than that in the untreated group ($P < 0.001$). Although there was no significant difference in the survival rate among the widowed, divorced, and the separated group ($P = 0.066$), the median survival time was 7 months (95% CI: 4.267-9.733) in the RT group, which was higher than 5 months (95% CI: 2.802-7.198) in the untreated group (Figure 5).

Overall survival of radiation-treated patients vs control after PSM stratification by tumor size was performed. Patients with tumor size <1 cm did not undergo RT, and so there was no participation in the stratification. According to subgroup analysis, the survival rate of patients with tumor size 1-3 cm and >5 cm was significantly higher than that of untreated patients ($P = 0.003$ and $P < 0.001$, respectively). There was no significant difference in the survival rate between 3 and 5 cm group of patients, but the median survival was 7 months (95% CI: 1.404-12.596) in the radiation-treated patients, which was longer than 5 months (95% CI: 3.233-6.767) in the untreated patients (Figure 6).

### 3.6 | Survival benefits of different RT modality

The modality of RT in this article included beam radiation, radioactive implants, radioisotopes, combination of beam with implants or isotopes, and other radiation methods or source not specified. Compared with untreated group, the results showed that the treated group patients with beam radiation, radioactive implants, radioisotopes or other radiation methods or sources not specified had better survival rate before and after PSM and the differences were statistically significant. The radiation combination of beam with implants or isotopes showed no statistical differences (Figure 7). However, there were only three patients who were treated with combination of beam and implants or isotopes. Because of the small sample size, further study is required to confirm these results.
The study showed that the prognosis of HCC patients associated with major vascular invasion was extremely dismal and the median survival time was very short, which was only 3 months in the untreated group. This result was consistent with most of the previous reports. Because of low tolerance to whole liver irradiation and concerns about radiation-induced liver disease (RILD), RT had been used less. Due to the improvement in RT technology and the application of computed tomography over the past decade, radiation can be precisely delivered, and the incidence of RILD can be significantly lowered than before, that is, within the range of acceptable adverse reactions.

The vascular invasion in this article included major branch(es) of portal or hepatic vein(s) and hepatic artery or vena cava. We performed subgroup stratification analysis of vascular invasion. With vascular invasion of codes 630 and 660, the survival rate of patients who underwent RT was significantly improved compared with those of untreated patients. Although there was no significant improvement in the survival of patients in code 635, the median survival time was higher than that of the untreated patients. Vascular invasion of code 635 involves multiple nodules in more than one lobe of liver.

### Table 3 (Continued)

| Variables                  | N (%) | 6-mo survival rate (%) | P       |
|----------------------------|-------|------------------------|---------|
| Derived AJCC Stage Group (6th) |       |                        |         |
| III                        | 427 (69.3) | 51.5                  | <0.001  |
| IV                         | 171 (27.8) | 22.1                  |         |
| Unk stage                  | 18 (2.9)  | 38.9                  |         |
| Grade (differentiated)     |       |                        |         |
| Well                       | 58 (9.4)  | 47.9                  | 0.339   |
| Moderately                 | 76 (12.3) | 46.8                  |         |
| Poorly                     | 51 (8.3)  | 40.9                  |         |
| Undifferentiated/anaplastic| 2 (0.3)   | 100.0                 |         |
| Unknown                    | 429 (69.6) | 41.4                 |         |
| AFP                        |       |                        |         |
| Elevated                   | 455 (73.9) | 41.0                  | 0.003   |
| Within normal limits       | 75 (12.2)  | 61.7                  |         |
| Unknown                    | 86 (14.0)  | 36.1                  |         |
| Fibrosis score             |       |                        |         |
| 0-4 (F0)                   | 32 (5.2)   | 44.7                  | 0.381   |
| 5-6 (F1)                   | 155 (25.2) | 47.9                  |         |
| Unknown                    | 429 (69.6) | 40.9                  |         |

AJCC, American Joint Committee on Cancer.

### Table 3 (Continued)

| Variables                  | N (%) | 6-mo survival rate (%) | P       |
|----------------------------|-------|------------------------|---------|
| Radiation                  |       |                        |         |
| Yes                        | 308 (50)  | 55.0                  | <0.001  |
| No                         | 308 (50)  | 31.0                  |         |
| Age                        |       |                        |         |
| ≤65                        | 416 (67.5) | 43.0                  | 0.459   |
| >65                        | 200 (32.5) | 42.6                  |         |
| Sex                        |       |                        |         |
| Male                       | 501 (81.3) | 43.2                  | 0.908   |
| Female                     | 115 (18.7) | 41.4                  |         |
| Marital status             |       |                        |         |
| Married                    | 344 (55.8) | 41.6                  | 0.834   |
| Single and unmarried       | 131 (21.3) | 40.1                  |         |
| Widowed, divorced, separated| 123 (20.0) | 49.2                  |         |
| Unknown                    | 18 (2.9)   | 41.6                  |         |
| Race                       |       |                        |         |
| White                      | 404 (65.6) | 46.4                  | 0.300   |
| Black                      | 89 (14.4)   | 40.8                  |         |
| Other                      | 123 (20.0)  | 33.2                  |         |
| Tumor size                 |       |                        |         |
| ≤1 cm                      | 3 (0.5)    | 33.3                  | 0.022   |
| 1-3 cm                     | 44 (7.1)    | 59.4                  |         |
| 3-5 cm                     | 93 (15.1)   | 44.5                  |         |
| >5 cm                      | 353 (57.3)  | 44.6                  |         |
| Unknown                    | 123 (20.0)  | 31.5                  |         |
| Vascular invasion          |       |                        |         |
| Code 630                   | 378 (61.4) | 44.1                  | 0.770   |
| Code 635                   | 160 (26.0)  | 40.7                  |         |
| Code 660                   | 78 (12.7)   | 41.0                  |         |
| TNM/T                      |       |                        |         |
| T3                         | 538 (87.3)  | 43.1                  | 0.587   |
| T4                         | 78 (12.7)   | 41.0                  |         |
| Lymph nodes                |       |                        |         |
| N0                         | 441 (71.6)  | 46.6                  | <0.001  |
| N1                         | 117 (19.0)  | 36.2                  |         |
| Nx                         | 58 (9.4)    | 28.7                  |         |
| Distant metastasis         |       |                        |         |
| M0                         | 427 (69.3)  | 51.5                  | <0.001  |
| M1                         | 171 (27.8)  | 22.1                  |         |
| Mx                         | 18 (2.9)    | 38.9                  |         |

(Continues)
or on surface of parenchyma. Extent of primary lesion and the location of the lesions also affected the effect of RT. Therefore, vascular invasion codes 630 and 635 are different in this article, because their lesions are different in scope and location, and have an effect on the assessment of RT. For code 635, systemic treatment may be more appropriate, and hence requires more researches to investigate.

At present, most of the literature reports are HCC with portal vein tumor thrombus. Portal vein invasion is also the most common manifestation seen. The hepatic vein/inferior vena cava is less explored, compared with PVTT. It is reported that surgical resection of hepatic vein/inferior vena cava can improve the survival rate of patients. It has been reported that TACE combined with RT can improve the survival rate of HCC patients with a tumor thrombus in the inferior vena cava and right atrium. Hepatic artery tumor invasion is quite rare and the number of cases seen till date is few, and so the research reports were relatively less.

We performed subgroup stratification analysis of RT modalities. Almost all the RT modalities significantly improved the survival rate of patients, but this paper did not report adverse reactions. With advances in the imaging technology and further innovative RT technologies, such as three-dimensional conformal RT (3D-CRT), stereotactic body ablative RT (SABR) and particle beam therapies, it is a pleasure with more precise and less adverse reactions. RT is more widely applied in patients with HCC. In addition, internal RT is gradually taken seriously.

Although there is no clear guidance on the value of RT in advanced HCC, several comparative studies have demonstrated the role of RT in the treatment of HCC patients, including the improvement of survival in HCC patients with vascular invasion. Nakazawa et al compared sorafenib combined with RT for patients with unresectable HCC and with PVTT, and the results showed that the RT group had significantly longer median survival time than sorafenib group (median survival, 10.9 vs 4.8 months; \( P = 0.025 \)).

Some scholars suggested that direct RT for tumor thrombosis can improve the patient’s survival rate. Choi

### Table 4: Multivariate predictors of overall mortality in the propensity-matched sample

| Predictors                                    | HR   | 95% CI       | P value |
|-----------------------------------------------|------|--------------|---------|
| Radiation (vs untreated)                      | 0.625| 0.522-0.749  | <0.001  |
| Tumor size 1-3 cm (vs ≤1 cm)                  | 1.138| 0.344-3.766  | 0.832   |
| Tumor size 3-5 cm (vs ≤1 cm)                  | 1.363| 0.426-4.359  | 0.602   |
| Tumor size >5 cm (vs ≤1 cm)                   | 1.528| 0.484-4.817  | 0.47    |
| Code 635 (vs Code 630)                        | 1.006| 0.813-1.246  | 0.954   |
| Code 660 (vs Code 630)                        | 0.894| 0.679-1.178  | 0.427   |
| TNM/T4 (vs T3)                                | 0.894| 0.679-1.178  | 0.427   |
| Lymph nodes N1 (vs N0)                        | 1.153| 0.916-1.451  | 0.225   |
| Lymph nodes Nx (vs N0)                        | 1.188| 0.867-1.628  | 0.284   |
| Distant metastasis M1 (vs M0)                 | 1.852| 1.508-2.273  | <0.001  |
| AJCC Stage IV (vs III)                        | 1.852| 1.508-2.273  | <0.001  |
| Grade moderately (vs Well)                    | 1.275| 0.863-1.883  | 0.223   |
| Grade poorly (vs Well)                        | 1.407| 0.925-2.139  | 0.111   |
| Grade undifferentiated/anaplastic (vs Well)   | 0.597| 0.079-4.523  | 0.618   |
| AFP within normal limits (vs elevated)        | 0.671| 0.504-0.895  | 0.007   |
| Fibrosis score 5-6 (F1) (vs F0)               | 1.082| 0.695-1.686  | 0.727   |

AJCC, American Joint Committee on Cancer.

### Table 5: Multivariate predictors of survival in radiation-treated patient (n = 308)

| Predictors                                    | HR   | 95% CI       | P value |
|-----------------------------------------------|------|--------------|---------|
| Age >65 (vs ≤65)                              | 0.999| 0.735-1.358  | 0.993   |
| Female (vs Male)                              | 1.044| 0.731-1.493  | 0.811   |
| Single and unmarried (vs Married)             | 0.538| 0.347-0.834  | 0.006   |
| Widowed, divorced, separated (vs Married)     | 1.013| 0.702-1.460  | 0.947   |
| Black (vs White)                              | 1.019| 0.674-1.540  | 0.93    |
| Other (vs White)                              | 0.924| 0.617-1.384  | 0.702   |
| Tumor size 3-5 cm (vs 1-3 cm)                 | 1.868| 0.970-3.599  | 0.062   |
| Tumor size >5 cm (vs 1-3 cm)                  | 1.836| 1.050-3.211  | 0.033   |
| Code 635 (vs Code 630)                        | 0.845| 0.603-1.186  | 0.331   |
| Code 660 (vs Code 630)                        | 1.046| 0.667-1.643  | 0.844   |
| TNM/T4 (vs T3)                                | 1.046| 0.667-1.643  | 0.844   |
| Lymph nodes N1 (vs N0)                        | 1.215| 0.822-1.794  | 0.329   |
| Distant metastasis M1 (vs M0)                 | 3.197| 2.287-4.469  | <0.001  |
| AJCC Stage IV (vs III)                        | 3.197| 2.287-4.469  | <0.001  |
| Grade moderately (vs Well)                    | 1.183| 0.665-2.105  | 0.567   |
| Grade poorly (vs Well)                        | 1.418| 0.783-2.569  | 0.249   |
| Grade undifferentiated/anaplastic (vs Well)   | 0.606| 0.071-5.189  | 0.647   |
| AFP within normal limits (vs elevated)        | 0.577| 0.364-0.915  | 0.019   |
| Fibrosis score 5-6 (F1) (vs F0)               | 2.506| 1.107-5.674  | 0.028   |

AJCC, American Joint Committee on Cancer.
et al demonstrated treatment of HCC patients accompanied by PVTT with localized concurrent chemoradiotherapy. RT included both primary tumor and PVTT. The results showed that the overall survival of patients with both primary tumor and PVTT was the longest (median, 16.7 months), survival neither in tumor nor in PVTT was
median, 8.4 months, and survival in the tumor alone was median, 16.0 months. The role of RT in the treatment of HCC should be paid more and more attention. An informal committee of the National Cancer Institute’s Radiation Research Program suggested RT as a curative local therapy and should be incorporated into the BCLC staging system, and recommended RT as a palliative treatment for HCC patients with vascular invasion. The committee emphatically recommended combination of RT with regional or systemic therapy for advanced HCC.

Single treatment such as RT or other therapy alone is unsatisfactory for improving the survival. Hence, there is a lot of research going on to explore the common survival benefit of multiple treatments. RT was recommended in combination with regional or systemic therapy, and as a palliative measure. A systematic meta-analysis showed that the survival rate for TACE plus RT was significantly better than TACE alone. A retrospective analysis was performed on HCC patients with main portal vein tumor thrombus (MPVTT) to evaluate the therapeutic effect of the percutaneous transhepatic portal vein stenting and transarterial chemoembolization (PTPVS-TACE) combined with or without 3-dimensional conformal RT (3DCRT). The study showed that the cumulative survival rate was significantly improved in patients combined with RT. The

FIGURE 6 Kaplan-Meier overall survival curves of radiation-treated patients vs control after propensity score matching stratified by type of tumor size 1-3 cm (A), 3-5 cm (B) and >5 cm (C).

FIGURE 7 Kaplan-Meier overall survival curves of different radiotherapy methods treated patients vs control (A) before and (B) after propensity score matching. 0 = Control; 11 = Beam radiation; 12 = Radioactive implants; 13 = Radioisotopes; 14 = Combination of beam with implants or isotopes; 15 = Radiation, NOS method or source not specified.
360-day cumulative survival rate with RT was 32.5%, and that without RT was 6.9% (P < 0.01). A randomized trial of an academic tertiary care center from Asan Medical Center compared TACE plus radiotherapy with sorafenib treatment for patients with advanced hepatocellular carcinoma and macroscopic vascular invasion. The result showed that TACE plus radiotherapy was well tolerated and had a higher progression-free survival rate and less adverse reactions than sorafenib.

Although this was a large sample study and the follow-up time was sufficiently long enough, SEER data lacked the record of HCC etiology, liver function index, and performance status. BCLC liver cancer scoring system included liver function score and performance status. This article was based on a simple classification of vascular invasion by Collaborative Stage Data Collection System Coding Instructions. However, it was still not detailed enough. For example, HCC invaded the different branches of the portal vein to form a tumor thrombus, which may have an effect on radiotherapy. We hope to refine this section in subsequent forward-looking articles. Although the database contains specific radiotherapy and surgical treatment methods, the lack of chemotherapy content has a certain impact on the evaluation of radiotherapy, which is the limitation of this manuscript. Therefore, we need more detailed data to evaluate the efficacy and adverse reactions of RT. In addition, this was a retrospective study. Although PSM was used to minimize the selection bias of the radiation-treated group, other biases that were not considered probably existed. More studies especially randomized controlled trials are required to evaluate the therapeutic effect of RT.

In conclusion, we have shown that RT provides another treatment and improves survival in HCC patients with vascular invasion, especially for tumor(s) confined to one lobe and not on the surface of the liver. RT is an effective local therapy, and combination with other regional or systemic therapies might be a more meaningful measure.

CONFLICT OF INTEREST

All the authors have no conflicts of interests to declare.

ORCID

Qiuyan Lin https://orcid.org/0000-0002-4508-8726

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65(2):87-108.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-E386.
3. Chen CK, Yang CY, Hua KT, et al. Leukocyte cell-derived motaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment. *Hepatology*. 2014;59(3):974-985.
4. Marshall A, Alexander G. Vascular invasion leaves its mark in hepatocellular carcinoma. *J Hepatol*. 2011;55(6):1174-1175.
5. Pesí B, Ferrero A, Grazi GL, et al. Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. *Am J Surg*. 2015;210(1):35-44.
6. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology*. 1999;29(1):62-67.
7. Cheung TK, Lai CL, Wong BC, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. *Aliment Pharmacol Ther*. 2006;24(4):573-583.
8. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. *J Clin Oncol*. 2010;28(25):3994-4005.
9. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet*. 2018;391(10127):1301-1314.
10. Yang JD, Mannelithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. *Hepatology*. 2017;68(1):78-88.
11. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology*. 2006;131(2):461-469.
12. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. *N Engl J Med*. 1995;332(19):1294-1296.
13. Rossi S, Ravetta V, Rosa L, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. *Hepatology*. 2011;53(1):136-147.
14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359(4):378-390.
15. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. *J Clin Oncol*. 2006;24(26):4293-4300.
16. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *J Hepatol*. 2012;57(4):821-829.
17. Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. *Hepatology*. 2017;66(2):510-517.
18. Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. *J Hepatol*. 2016;65(5):938-943.
19. Biederman DM, Titano JJ, Korff RA, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. *J Vasc Interv Radiol*. 2018;29(1):30-37. e2.
20. Surveillance, Epidemiology and End Results Program. About the SEER Program, 2018, 2018, http://seer.cancer.gov/about. Accessed January 21, 18.
21. Fritz AG. *International classification of diseases for oncology: ICD-O*, 3rd edn. Geneva: World Health. Organization; 2000:vii:240 p.
22. Pattanayak CW, Rubin DB, Zell ER. Propensity score methods for creating covariate balance in observational studies. *Rev Esp Cardiol.* 2011;64(10):897-903.

23. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. *Hepatology.* 2000;32(2):233-238.

24. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. *World J Gastroenterol.* 2006;12(47):7561-7567.

25. Takamatsu S, Kozaka K, Kobayashi S, et al. Pathology and images of radiation-induced hepatitis: a review article. *Jpn J Radiol.* 2018.

26. Benson R, Madan R, Kilambi R, Chander S. Radiation induced liver disease: a clinical update. *J Egypt Natl Canc Inst.* 2016;28(1):7-11.

27. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. *Yonsei Med J.* 2009;50(5):601-612.

28. Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. *J Natl Cancer Inst.* 2016;108(9):djw133.

29. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. *Gut.* 2001;48(1):103-109.

30. Duan F, Yu W, Wang Y, et al. Trans-arterial chemoembolization and external beam radiation therapy for treatment of hepatocellular carcinoma with a tumor thrombus in the inferior vena cava and right atrium. *Cancer Imaging.* 2015;11(1):661-669.

31. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2002;54(1):150-155.

32. Paik EK, Kim MS, Choi CW, et al. Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma. *Radiat Oncol J.* 2015;33(3):233-241.

33. Kalogeridi MA, Zygogianni A, Kyrgias G, et al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. *World J Hepatol.* 2015;7(1):101-112.

34. Kondo Y, Kimura O, Shimosegawa T. Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. *World J Gastroenterol.* 2015;21(1):94-101.

35. Nakazawa T, Hidaka H, Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. *BMC Gastroenterol.* 2014;14:84.

36. Choi Y, Kim JW, Cha H, Han KH, Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. *J Radiat Res.* 2014;55(1):113-120.

37. Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. *JAMA Oncol.* 2015;1(6):756-765.

38. Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. *Cancer.* 2009;115(6):1245-1252.

39. Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. *JAMA Oncol.* 2018;4(5):661-669.

---

**How to cite this article:** Lin Q, Huang X, Zhong C, Luo T, Zeng X, Chen S. Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database. *Cancer Med.* 2019;8:515–526. [https://doi.org/10.1002/cam4.1937](https://doi.org/10.1002/cam4.1937)